Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CSCI Stock Forecast 2025-2026
$3.49
Current Price
$11.08M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CSCI Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CSCI Price Momentum
-2.2%
1 Week Change
+0.3%
1 Month Change
-24.5%
1 Year Change
+26.0%
Year-to-Date Change
-53.7%
From 52W High of $7.54
+78.1%
From 52W Low of $1.96
📊 TOP ANALYST CALLS
Did CSCI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cosciens is one of their latest high-conviction picks.
Latest CSCI Stock Price Targets & Analyst Predictions
CSCI has shown a year-to-date change of 26.0% and a 1-year change of -24.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CSCI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CSCI Analyst Ratings
0
Buy
0
Hold
0
Sell
CSCI Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.49
Latest CSCI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CSCI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Jul 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| May 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Apr 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Mar 28, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Mar 30, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $1.50 |
| Oct 25, 2021 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Nov 9, 2015 | Canaccord Genuity | Buy | Upgrade | $0.00 | |
| Apr 14, 2015 | H.C. Wainwright | Buy | Upgrade | $0.00 | |
| Jul 17, 2014 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Jul 25, 2013 | Euro Pacific Capital | Hold | Initiates | $0.00 | |
| Jan 3, 2013 | McNicoll Lewis Vlak | Buy | Upgrade | $0.00 | |
| Dec 31, 2012 | Canaccord Genuity | Hold | Maintains | $2.50 | |
| Oct 12, 2012 | Bloom Burton & Co. | Sell | Maintains | $2.00 |
Coscens Biopharma Inc. (CSCI) Competitors
The following stocks are similar to Cosciens based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CSCI
Cosciens Biopharma
mkt cap
11.44M
Coscens Biopharma Inc. (CSCI) Financial Data
Coscens Biopharma Inc. has a market capitalization of $11.08M with a P/E ratio of -0.6x. The company generates $9.03M in trailing twelve-month revenue with a -194.5% profit margin.
Revenue growth is -27.1% quarter-over-quarter, while maintaining an operating margin of -241.1% and return on equity of -152.0%.
Valuation Metrics
Market Cap
$11.08M
Enterprise Value
$-552,912
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
-27.1%
Gross Margin
+29.5%
Operating Margin
-241.1%
Net Margin
-194.5%
EPS Growth
+2.0%
Financial Health
Cash/Price Ratio
+125.3%
Current Ratio
2.9x
Debt/Equity
21.9x
ROE
-152.0%
ROA
-23.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Coscens Biopharma Inc. (CSCI) Business Model
About Coscens Biopharma Inc.
What They Do
Develops novel therapeutic solutions in healthcare.
Business Model
Coscens Biopharma Inc. operates in the biotechnology sector by researching and commercializing drugs that target unmet medical needs, particularly in rare diseases. The company generates revenue through the development of innovative therapies, leveraging partnerships with research institutions to enhance its product pipeline and expedite the delivery of its medicines to the market.
Additional Information
Coscens Biopharma emphasizes rigorous scientific research and development, positioning itself as a significant contributor to advancements in healthcare. Its focus on breakthrough therapies and collaborations within the biopharmaceutical industry highlights its commitment to addressing critical medical challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.
Country
Canada
IPO Year
2000
Website
www.cosciensbio.comCoscens Biopharma Inc. (CSCI) Latest News & Analysis
Latest News
Quick Summary
COSCIENS Biopharma (NASDAQ: CSCI, TSX: CSCI) has received six director nominations from Goodwood Fund and Puccetti Funds for its upcoming Annual and Special Meeting of Shareholders.
Why It Matters
Director nominations can signal potential changes in company strategy or governance, impacting COSCIENS's future direction and stock performance, thus influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
1 month ago
Quick Summary
COSCIENS Biopharma Inc. has repositioned as a natural-based product company, reported $13.8M cash, and advanced Phase 2 trials for Avenanthramide tablets after successful Phase 1 results. Anna Biehn is new CEO.
Why It Matters
COSCIENS Biopharma's shift to a natural-based product focus, cash position, and clinical trial advancements signal potential growth opportunities, impacting future revenue and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
2 months ago
Quick Summary
COSCIENS Biopharma Inc. reported Q4 revenues of $9.6M, up 35.2% YOY. The company ended the quarter with $16.4M in cash, after repositioning as a natural-based product firm.
Why It Matters
COSCIENS Biopharma's shift to a pure-play natural-based product company, alongside a 35.2% revenue increase and strong cash position, indicates potential for growth and operational efficiency.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
COSCIENS Biopharma Inc. (NASDAQ: CSCI, TSX: CSCI) announces that the Ontario Securities Commission has accepted its application for a management cease trade order following a previous default announcement.
Why It Matters
COSCIENS Biopharma's management cease trade order signals regulatory scrutiny and potential operational challenges, raising concerns about governance and financial stability, affecting investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
3 months ago
Quick Summary
COSCIENS Biopharma Inc. (NASDAQ: CSCI) announced a potential delay in filing its annual financial statements and related documents beyond the March 31, 2025 deadline due to merger-related matters.
Why It Matters
A potential delay in financial filings raises concerns about COSCIENS Biopharma's transparency and stability, which could negatively impact investor confidence and stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
COSCIENS Biopharma Inc. (NASDAQ: CSCI, TSX: CSCI) announced the initiation of a Phase 2a clinical study for its avenanthramides product aimed at managing inflammation-related conditions.
Why It Matters
The initiation of a Phase 2a clinical trial for COSCIENS' avenanthramides product indicates progress in its pipeline, potentially boosting future revenue and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CSCI Stock
What is Coscens Biopharma Inc.'s (CSCI) stock forecast for 2025?
Analyst forecasts for Coscens Biopharma Inc. (CSCI) are not currently available. The stock is trading at $3.49.
Is CSCI stock a good investment in 2025?
Analyst ratings for CSCI are not currently available. The stock is currently trading at $3.49. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CSCI stock?
Price predictions from Wall Street analysts for CSCI are not currently available. The stock is trading at $3.49.
What is Coscens Biopharma Inc.'s business model?
Coscens Biopharma Inc. operates in the biotechnology sector by researching and commercializing drugs that target unmet medical needs, particularly in rare diseases. The company generates revenue through the development of innovative therapies, leveraging partnerships with research institutions to enhance its product pipeline and expedite the delivery of its medicines to the market.
What is the highest forecasted price for CSCI Coscens Biopharma Inc.?
Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $3.49.
What is the lowest forecasted price for CSCI Coscens Biopharma Inc.?
Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $3.49.
What is the overall CSCI consensus from analysts for Coscens Biopharma Inc.?
Analyst ratings for CSCI are not currently available. The stock is trading at $3.49.
How accurate are CSCI stock price projections?
Stock price projections, including those for Coscens Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 20, 2025 5:51 PM UTC